Premium
USE OF [ 123 I]‐2‐IODO‐ l ‐PHENYLALANINE AS A TUMOR IMAGING AGENT IN TWO DOGS WITH SYNOVIAL CELL SARCOMA
Author(s) -
PEREMANS K.,
KERSEMANS V.,
LIUTI T.,
VANDERMEULEN E.,
CORNELISSEN B.,
GIELEN I.,
DE SPIEGELEER B.,
MERTENS J.,
BURVENICH C.,
SLEGERS G.
Publication year - 2007
Publication title -
veterinary radiology and ultrasound
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.541
H-Index - 60
eISSN - 1740-8261
pISSN - 1058-8183
DOI - 10.1111/j.1740-8261.2007.00281.x
Subject(s) - medicine , phenylalanine , nuclear medicine , in vivo , scintigraphy , synovial sarcoma , sarcoma , pathology , cancer research , chemistry , biochemistry , amino acid , microbiology and biotechnology , biology
[ 123 I]‐iodo‐ l ‐phenylalanine was successfully evaluated for gamma camera imaging in vivo in tumor‐bearing athymic mice and in humans with brain tumors. Here, we report the use of this tracer in two dogs with synovial cell sarcoma of the tarsus. [ 123 I]‐iodo‐ l ‐phenylalanine was quantitatively prepared as a kit formulation using the Cu 1+ ‐assisted nucleophilic exchange. Rapid [ 123 I]‐2‐iodo‐ l ‐phenylalanine tumor accumulation was observed with good tumor to background contrast and rapid clearance in these two dogs. This radiopharmaceutical is a promising alternative tumor tracer to overcome the known limitations of 18 F‐fluorodeoxyglucose and, when labelled with radioiodine‐131, has the potential to be used for therapeutic purposes.